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ess: maritta.orth@ruhrSummary Theophylline is effective in the treatment of central apneas and
periodic breathing. In obstructive sleep apnea syndrome (OSAS), results of
pharmacological monotherapy with theophylline are inconsistent. The present study
investigates whether additional theophylline in patients with OSAS and continuous
positive airway pressure (CPAP) therapy might improve ventilation, lower effective
CPAP pressure levels or affect sleep architecture.
Patients with mild to moderate OSAS (mean apnea index [AI] 12.8711.7) and
CPAP therapy (AutosetTM system; n ¼ 16; all male) received either 900mg of oral
sustained-release theophylline (T) or placebo (P) on two separate nights, 3 days
apart, using a randomized double-blind crossover study design.
There was no change in AI (T: 0.771.4 vs. P: 0.770.6/h; P ¼ 0:3) or
apnea–hypopnea index (AHI; T: 4.373.3 vs. P: 4.573.7/h; P ¼ 0:84) when
theophylline was added to CPAP therapy. We observed no difference in mean CPAP
pressure (T: 6.972.1 vs. P: 6.771.9 cm H2O; P ¼ 0:7) or 95% pressure percentiles (T:
9.772.7 vs. P: 9.372.1 cm H2O; P ¼ 0:3) when nights with theophylline were
compared to placebo nights. Theophylline reduced significantly total sleep time (T:
290.6758.9 vs. P: 338.0740.1min; P ¼ 0:02) and thus sleep efficiency (SE; T:
70.5714.9%, P: 82.0770.5%; P ¼ 0:005). Rapid eye movement and slow wave sleep
were not affected.Elsevier Ltd. All rights reserved.
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Table 1 Study design.
Day
Patient election/consent
Clinical history
Physical examination
Lung function/rhinomanometry
Polysomnography
AutosetTM
Study medication (placebo/the
Serum theophylline
M.M. Orth et al.472Oral theophylline did not show any additional effects on ventilation parameters
or pressures in patients with mild to moderate OSAS once CPAP therapy has been
successfully installed. SE was reduced with theophylline with unchanged sleep
architecture. The role of oral theophylline may be in patients with predominately
central apneas not eligible for ventilation therapy or severe cases.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnea syndrome (OSAS) affects at
least 2% of women and 4% of men.1 Since
continuous positive airway pressure (CPAP) was
introduced, it has become the treatment of choice
in the majority of patients.2 However, long-term
acceptance of CPAP is hampered in some patients
by side effects like mask discomfort or dryness of
nose or mouth.3 Patients could therefore benefit
from additional drug treatment through reduction
of apneic episodes or ventilation pressures and thus
side effects. Various pharmacological agents in-
cluding tricyclic antidepressants, serotonine reup-
take inhibitors or antagonists and especially
theophylline have been investigated in the treat-
ment of OSAS.4 Results of the beneficial effect of
monotherapy of theophylline strongly depend on
the study design, the cohort and the type of
administration. In patients with OSAS, however,
who tolerate CPAP therapy, monotherapy with
theophylline is not an option.
We therefore investigated the effects of theo-
phylline on the number of apneic events and sleep
quality, as well as the potential to reduce ventila-
tion pressures in combination therapy with CPAP.Patients and methods
Subjects
A total of 16 male patients with documented OSAS
underwent six overnight polysomnographic sleep1
x
x
ophylline)studies in a double-blind placebo-controlled cross-
over study design (see Table 1). The following
patients were excluded from the study: previously
taking theophylline, patients with epilepsy or
chronic obstructive pulmonary disease, pregnant or
lactating women. The study was approved by the
Ethics Committee of the Ruhr-Universita¨t Bochum,
and all patients gave their written informed consent
prior to the study. Subjects were instructed to avoid
caffeine and alcohol for the time of the study. Initial
evaluation included a clinical history and physical
examination, chest radiogram, electrocardiogram,
ultrasoundcardiogram, allergy test, rhinomanometry
and pulmonary function tests (bodyplethysmogra-
phy, spirometry, arterial blood gas analyses).
Sleep studies
The following polysomnographic parameters were
recorded (Alice IV, Healthdyne): electroencephalo-
gram (C3/A2), submental and double-side tibialis
anterior electromyogram, electrooculogram, thor-
aco-abdominal movements (respiratory inductive
plethysmography), airflow at the mouth and nos-
trils, electrocardiogram and arterial oxygen satura-
tion by finger oximeter. Sleep was scored according
to Rechtschaffen and Kales.5
Further definitions:2 3
x
x
x
x x
x x
xSleep efficiency
(SE):Total sleep time (TST) divided
by compared to time in bed
(TIB).Apnea: Cessation of airflow at the
mouth and nose for 10 s or
more.4 5 6 7
x x x
x
x
x x
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OSAS, CPAP and theophylline 473Obstructive
apnea:In the presence of ongoing
thoraco-abdominal movements.Central apnea: With cessation of thoraco-
abdominal movement.Mixed apnea: Beginning as a central, ongoing
as an obstructive apnea.Hypopnea: Reduction of oral/nasal airflow
of at least 50% together with
oxygen desaturation X4% and/
or arousal.Table 2 Anthropometric, lung function and blood
gas data in patients with OSAS (n ¼ 16).
Parameter Mean7SD
Age (yr) 56.979.7
BMI (kg/m2) 31.776.8
Rt (cm H2O/l/s) 2.170.6
ITGV (% pred.) 95.9720.8
FEV1 (% pred.) 105.9715.1
FVC (% pred.) 105.8713.9
FEV1/FVC (% pred.) 99.275.8
PaO2 (mmHg) 81.778.3
PaCO2 (mmHg) 39.472.5OSAS was diagnosed when polysomnography re-
vealed an apnea index (AI)X10 in combination with
clinical symptoms suggestive of OSAS. CPAP was
initiated using a self-setting device (AutosetTM)
during the second night with polysomnography
(Table 1). On day 3 the patients received randomly
(according to a computerized list) either placebo or
900mg theophylline (Unilairs, 3M Medica, Borken,
Germany) orally, at noon. In the following night,
CPAP was again adjusted by AutosetTM under
polysomnographic control. Venous blood sample to
assess serum theophylline level was taken at 8 a.m.
on day 4. Days 4 and 5 served as washout period. On
noon of day 6 patients received the crossover
medication. Again, on the following polysomno-
graphic night CPAP was adjusted automatically by
the self-setting device. Finally, on day 7 at 8 a.m.
venous blood sample was taken to assess serum
theophylline level.
Continuous positive airway pressure self-
setting device
The AutosetTM system (ResMed Ltd., Australia) is an
auto-titrated, CPAP device designed to conduct
either a diagnostic recording or a therapeutic
trial.6 Mask airflow is registrated by pneumotacho-
graph. The nasal cannulae are connected to a
pressure transducer in the device. The internal
pressure transducer and the software allow estima-
tion of nasal airflow and the flow/time relation-
ship.6 Snoring is assessed by analyzing the flow
signal following band-pass filtering.7 Additionally,
an external digital oximeter is provided. The
threshold for the apnea count is a reduction in
airflow top25% and for the apnea–hypopnea count
to p50% compared with the recent average (time
constant 100 s).8 AI and apnea–hypopnea index
(AHI) are assessed independently by the software
and calculated per hour of recording.8 Hypopnea
index is not recorded specifically. Pressure is
initially set to 4 cm H2O and increased in case of
apneas longer than 10 s, snoring and airflow
limitation. The maximum pressure limit is 20 cm
H2O. If no further respiratory abnormalities aredetected, the pressure is slowly decreased to 4 cm
H2O. The following parameters were read from the
AutosetTM system after each study night: mean
pressure, maximum pressure and 95th percentile of
pressure.
Statistical analysis
All values are either given as frequencies or
mean7standard deviation (SD). All continuous vari-
ables were tested for normal distribution by
Kolmogorov–Smirnov test. Student’s t-test for
paired samples was used for comparison of para-
metric data and Wilcoxon’s signed rank test was
employed for variables with non-parametric dis-
tribution. Statistical significance was assumed
below a P-value of 5%.Results
The anthropometric data and results of pulmonary
function test and arterial blood gas analyses for the
16 male subjects with OSAS are presented in Table
2. On average the group was obese, normoxemic
and normocapnic. Bodyplethysmography and spiro-
metry showed no evidence of airway obstruction.
Mean serum theophylline level was 0.1570.24mg/
dl after placebo and 9.573.3mg/dl after verum.
No adverse effects or events were reported in the
theophylline or placebo group.
Ventilatory and oxygen saturation data, sleep
stages and arousal results at baseline under
AutosetTM as well as under AutosetTM/placebo and
AutosetTM/theophylline are presented in Table 3. As
to be expected both AI and AHI were significantly
reduced under AutosetTM. However, the differences
between AutosetTM/placebo night and AutosetTM/
theophylline night were not significant. Oxygen
saturation was improved by AutosetTM; however,
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Table 3 Results of ventilatory data, oxygen saturation, sleep analyses and AutosetTM readout data.
Baseline AutosetTM P-value AutosetTM +
placebo
AutosetTM +
theophylline
P-value
Apnea index (/h) 12.8711.7 2.473.2 0.001a 0.770.6 0.771.4 0.3a
Maximal apnea duration (s) 43.2723.3 20.9712.7 0.001b 18.1710.9 11.8712.9 0.2a
Obstructive apneas (n) 32.1732.6 2.578.2 0.001a 0.670.9 0.370.6 0.43a
Central apnea index (n) 17.2718.9 10.3715.7 0.14a 3.173.0 2.975.4 0.55a
Mixed apnea index (n) 17.5722.9 0.672.0 0.003a 0.070.0 0.070.0
AHI (/h) 37.9717.9 7.976.4 0.001b 4.573.7 4.373.3 0.84a
Maximal hypopnea duration (s) 78.9739.9 47.9718.9 0.001a 44.6718.9 45.0716.5 0.93b
Mean oxygen saturation (%) 91.373.2 94.771.6 0.001b 94.971.1 94.871.4 0.41a
Minimal oxygen saturation (%) 76.7710.4 89.374.7 0.001b 89.474.4 89.373.7 0.89b
TST (min) 334.3744.0 324.3749.5 0.68b 338.0749.1 290.6758.9 0.02b
TIB (min) 433.6752.9 442.0730.1 0.71b 417.7747.9 421.0732.5 0.81b
SE (%) 73.1725.2 73.2711.4 0.91b 82.0711.1 70.5714.9 0.005b
Wake (%) 16.8717.1 16.5714.5 0.95b 9.9710.5 20.9716.5 0.03b
Slow wave (%) 10.379.9 13.8711.8 0.09b 13.3710.6 12.479.6 0.54b
REM sleep (%) 14.677.6 16.97711.3 0.45a 17.277.5 15.576.5 0.46b
Arousal index (events/h) 17.2714.3 8.978.7 o 0.001 10.0710.1 8.179.8 0.33a
Mean pressure (cm H2O) 7.071.7 6.771.9 6.972.1 0.7
b
Maximum pressure (cm H2O) 11.672.3 11.072.8 11.372.9 0.61
b
95th percentile 10.172.0 9.372.1 9.772.7 0.3b
Note: Columns show the comparison with and without CPAP therapy and under CPAP therapy with placebo and theophylline.
aWilcoxon’s signed rang test.
bStudent’s t-tests.
M.M. Orth et al.474there was no additional improvement by theophyl-
line. Furthermore, apnea duration showed no
difference between placebo and verum (Table 3).
As compared to placebo TST shortened and wake
time was prolonged under theophylline medication.
As a consequence, SE was reduced by adding
theophylline to CPAP therapy. Rapid eye movement
(REM) and slow wave sleep as well as arousal index,
however, were not significantly influenced by
theophylline.
AutosetTM pressure values remained unchanged
under additional medication with theophylline
(Table 3). Neither the mean or maximum pressure
nor the pressure in the 95th percentile were
affected by the additional medication.Discussion
The major findings of this study were: (1) Theophyl-
line administered orally (900mg) did not further
reduce the number of apneas in patients with OSAS
and CPAP therapy. (2) Short-term application of
theophylline did not lead to lower ventilation
pressures with an AutosetTM CPAP device. (3) SE
decreased with additional theophylline as a func-
tion of decreased TST.Drug treatment for OSAS yielded inconsistent
results although widely investigated. The most
objective data are available on opioid antago-
nists/nicotine groups and theophylline.4,9 Mulloy
and McNicholas10 examined the effect of 800mg
theophylline taken at night for 4 weeks in 12
patients with OSAS in a double-blind placebo-
controlled crossover trial. Compared to placebo
obstructive apneas and hypopneas could be sig-
nificantly reduced by theophylline whereas central
and mixed apneas/hypopneas remained un-
changed. In contrast, Guilleminault and Hayes11
investigated acute and chronic administration of
theophylline in OSAS patients. They found no
change either in ventilatory parameters or sleep
quality under theophylline medication; however,
the study was neither placebo controlled nor
double blinded. Hein et al.12,13 saw an initial
improvement of AHI at the beginning of therapy
with 375mg of sustained-release oral theophylline,
but the initial improvement of AHI was not seen in
the medium-term therapy. The authors hypothe-
sized that probably night-to-night variability espe-
cially in mild to moderate sleep apnea could be
responsible for the initial improvement of AHI
under theophylline medication.
Since effects are inconsistent and CPAP remains
the cornerstone of OSAS therapy, we considered
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OSAS, CPAP and theophylline 475theophylline not suitable for monotherapy in our
cohort and used a randomized double-blind place-
bo-controlled crossover study design to detect
possible effects of theophylline in addition to CPAP
therapy. In our study, we did not see any additional
reduction of the numbers of apneas regardless
whether they were classified as obstructive or
central when theophylline was added to CPAP
therapy (Table 3). This seems to be in contrast to
the findings of Javaheri et al.,14 who studied the
effect of 5 days of oral theophylline therapy on
periodic breathing in patients with stable heart
failure with a similar study design. Theophylline
reduced the AHI significantly and this effect was
mostly due to a reduction of the number of central
apneas, whereas the number of obstructive apneas
remained unchanged. However, this study investi-
gated theophylline alone, which should only be
considered if patients are not eligible for CPAP
therapy.
Theophylline has been successfully used to treat
infants with periodic breathing and central ap-
nea,15,16 and to decrease Cheyne–Stokes breathing
in adults with heart failure.14 The proposed
mechanisms are the increase of skeletal muscle
contractility17 and the decrease of muscular fati-
gue in COPD patients.18 These properties might
improve upper airway muscle tone and may
facilitate the prevention of upper airway collapse
during sleep. In our study, however, we were unable
to document a significant reduction in ventilation
pressures with the AutosetTM device (Table 3). This
makes it unlikely that additional theophylline may
lead to a clinically relevant reduction of ventilation
pressures in order to reduce mask related side
effects of the CPAP therapy.
Theophylline has stimulating effects on the
central nervous system. It has been a con-
sistent finding throughout the majority of studies
involving sleep that theophylline increases
number of arousals and changes in sleep architec-
ture. Sleep quality was significantly disturbed
with a shorter sleep period time, increased
wakefulness and sleep stage changes in the study
by Mulloy and McNicholas.10 Espinoza et al.19 also
described adverse effects of theophylline on sleep
architecture, when aminophylline was given par-
enterally. The authors even concluded that part of
the improvement of ventilatory parameters by
theophylline may have been due to the deteriora-
tion of sleep quality.19 Our study adds further
evidence, since we could confirm a reduction of SE
in the theophylline nights (Table 3). This was mostly
due to the reduction of TST, whereas sleep
architecture did not change significantly in our
patients.Our study used an elaborate design to investigate
short-term effects of theophylline administration
on OSAS and sleep. It might be that chronic
theophylline medication may yield better results,
since a night-to-night variability cannot be ex-
cluded. Ventilation pressures were assessed by the
AutosetTM system, which may be a debatable
device to adjust pressures required to prevent
obstructive apneas. However, this system has been
evaluated in polysomnographic studies and is valid
for the detection of changes in clinically relevant
ranges.7 We investigated patients with mild to
moderate disease and effects of additional theo-
phylline may have been underestimated because
ventilation pressures were in the intermediate
range.
In conclusion, theophylline has no additional
short-term effects on the number apneas, arterial
oxygenation or ventilation pressures once CPAP
therapy has been successfully installed in patients
with mild to moderate OSAS. Theophylline had
adverse effects on sleep quality and should there-
fore not be routinely considered as additional
therapy in patients with OSAS eligible for CPAP
therapy. Theophylline may be beneficial in patients
with central sleep apnea syndrome who cannot be
treated by ventilation therapy or OSAS patients
with severe disease.Acknowledgements
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